Allogene Therapeutics, Inc. (ALLO) Cash Flow Statement

The gap between net income and operating cash flow is primarily driven by non-cash stock-based compensation and working capital timing, not by operational efficiency. In 2026Q1, a positive working capital change of $18.4M inflated operating cash flow relative to the loss, while 2026Q2's negative $18.4M swing reversed that effect, suggesting the underlying cash burn is more consistent than quarterly OCF/NI ratios imply. Investors should monitor the ex-working-capital cash burn, which appears to be running at roughly $30-40M per quarter, to gauge true liquidity consumption.

The trajectory shows a clear deceleration in cash burn, likely reflecting cost-cutting measures and a strategic pivot, but the absolute level remains high relative to the company's cash balance. With only $51.7M in cash, the current quarterly FCF of -$32.1M implies a runway of less than two quarters, assuming no additional financing or partnership inflows. This suggests that the company's survival is contingent on securing new capital or achieving a significant reduction in operating costs.

The near-zero CapEx is striking for a company that has invested heavily in internal manufacturing, indicating that either the facility is already built out or that capital costs are being absorbed elsewhere, possibly through operating leases or collaboration agreements. This low capital intensity may not persist if the company needs to scale manufacturing for late-stage trials or commercial launch. Investors should monitor whether future CapEx increases are required to support the ALLO-316 program, which could accelerate cash burn.

The large swings in working capital, particularly in 2026Q1 and 2026Q2, appear to be driven by timing of payments and receipts related to collaborations and clinical trial expenses, rather than operational efficiency. These swings obscure the underlying cash burn, which is more stable when adjusted for working capital. Analysts should focus on the ex-working-capital operating cash flow, which has been consistently negative in the $30-40M range, to assess the company's true liquidity needs.

Capital deployment is entirely focused on funding the clinical pipeline, with no shareholder returns, which is typical for a pre-commercial biotech. The negligible buyback in 2026Q2 is immaterial and likely reflects a minor offset to dilution from stock-based compensation. The company's capital allocation strategy appears to be preservation of cash, but the high burn rate and low cash balance suggest that future deployment will be constrained by the need to raise capital.

The cumulative gap between net income and operating cash flow is largely attributable to non-cash charges like stock-based compensation and depreciation, which totaled approximately $100M over the period. This divergence indicates that the company's cash burn is less severe than its accounting losses, but the absolute magnitude of both remains substantial. The persistent gap also suggests that the company is not generating any cash from operations, and the reliance on external financing is likely to continue.